Molecular diagnostics and personalized medicine: value-assessed opportunities for multiple stakeholders

Personalized Medicine

Volumn 7, Issue 2, 2010, Pages 143-161

  Blair, Edward D ^a  

^a Integrated Medicines Ltd   (United Kingdom)

Author keywords

Biologicals; Companion diagnostics; Drugs; Pharmaceuticals; Pharmacogenetics; Prediction; Prevention; Value assessment

Indexed keywords

ABACAVIR; CETUXIMAB; ENTECORT; GEFITINIB; MARAVIROC; PANITUMUMAB; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHRONIC DISEASE; DIAGNOSTIC PROCEDURE; DNA FINGERPRINTING; DNA SEQUENCE; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG UTILIZATION; ENTERITIS; FEASIBILITY STUDY; HEALTH CARE ORGANIZATION; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG CANCER; METASTASIS; PHARMACOGENETICS; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; PROTEOMICS; REVIEW; SEROLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

EID: 77949670386     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.10.1     Document Type: Review

References (27)

1. Spear BB, Heath-Chiozzi M, Huff J: Clinical application of pharmacogenetics. Trends Mol. Med. 7, 201-204 (2001).
2. Christensen CM, Grossman JH, Hwang J: The Innovator's Prescription: A Disruptive Solution for Health Care. McGraw-Hill, NY, USA (2009).
3. Davis JC, Furstenthal L, Desai AA et al.: The microeconomics of personalised medicine: today's challenge and tomorrow's promise. Nat. Rev. Drug Discov. 8(4), 279-286 (2009).
4. Durant J, Clevenbergh P, Halfon P et al.: Drug resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 353(9171), 2195-2199 (1999).
5. Brown G: The Living End: The Future of Death, Aging and Immortality. Palgrave MacMillan, Hampshire, UK (2008).
6. Overdevest JB, Theodorescu D, Lee JK: Utilizing the molecular gateway: the path to personalized cancer management. Clin. Chem. 55(4), 684-697 (2009).
7. Fore J, Wiechers IR, Cook-Deegan R: The effects of business practices, licensing, and intellectual property on development and dissemination of the polymerase chain reaction. J. Biomed. Discov. Collab. 1, 7 (2006)
8. Walker I, Newell H: Do molecularly targeted agents in oncology have reduced attrition rates? Nat. Rev. Drug Discov. 8, 15-16 (2009).
9. Booth B, Glassman R, Ma P: Oncology's trials. Nat. Rev. Drug Discov. 2, 609-610 (2003).
10. Blair ED: Assessing the value-adding impact of diagnostic-type tests on drug development and marketing. Mol. Diagn. Ther. 12(5), 331-337 (2008).
11. Blair ED: Why you should care about the innovative medicines initiative. CR Focus 12(7), 14-20 (2008).
12. Franz S: Pipeline problems are increasing the urge to merge. Nat. Rev. Drug Discov. 5, 977-979 (2006).
13. Trusheim MR, Berndt ER, Douglas FL: Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov. 6, 287-293 (2007).
14. Hughes B: The comparative effectiveness challenge. Nat. Rev. Drug Discov. 8, 261-263 (2009).
15. Lesko L: Personalized medicine: elusive dream or imminent reality? Clin. Pharmacol. Ther. 81(6), 807-816 (2007).
16. Hughes B: Novel risk-sharing scheme puts the spotlight on biomarkers. Nat. Rev. Drug Discov. 6, 945 (2007).
17. Carlson JJ, Garrison LP, Sullivan SD: Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals. J. Manag. Care Pharm. 15, 683-687 (2009).
18. Cook JP, Vernon JA, Manning R: Pharmaceutical risk-sharing agreements. Pharmacoeconomics 26, 551-556 (2008).
19. Blair ED: Predictive tests and personalised medicines. Drug Discovery World, 21st October (2009).
20. Hughes AR, Spreen WR, Mosteller M et al.: Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. Pharmacogenomics J. 8, 365-374 (2008).
21. Stephans EJ, Conti G, Keane M, Farber S: Does the economic downturn impact point of care? Point Care 8, 141 (2009).
22. Lyman GH, Cosler LE, Kuderer NM, Hornberger J: Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer - an economic analysis based on prognostic and predictive validation studies. Cancer 109(6), 1011-1018 (2007).
23. Hassett MJ, O'Malley AJ, Pakes JR, Newhouse JP, Earle CC: Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J. Natl Cancer Inst. 98(16), 1108-1117 (2006).
24. Levine DS: Gazing into the future. J. Life Sciences 3, 18-25 (2009)
25. Aspinall MG, Hamermesh RG: Realizing the promise of personalized medicine. Harv. Bus. Rev. 85(10), 108-117, 165 (2007)
26. Jimenez-Sanchez G, Silva-Zolezzi I, Hidalgo A, March S: Genomic medicine in Mexico: initial steps and the road ahead. Genome Res. 18, 1191-1198 (2008).
27. Lee HH, Morse SA, Olsvik ø: Nucleic Acid Amplification Technologies: Application To Disease Diagnosis. Birkhäuser Boston, MA, USA (1997).